Dexmedetomidine oromucosal gel for canine noise aversion — LIKELY

In dogs with noise aversion, does dexmedetomidine oromucosal gel vs placebo reduce acute anxiety signs during fireworks/thunderstorms?

Shelf #302 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: On New Year's Eve, in a randomised, double-blind, placebo-controlled clinical-field study of 182 dogs with a history of fireworks anxiety, an excellent or good treatment effect was reported for 72% of dexmedetomidine oromucosal gel dogs (64/89) vs 37% on placebo (34/93), with the overall treatment effect statistically significant at P<0.0001 and significantly fewer signs of fear and anxiety on treatment (P<0.0314) (Korpivaara 2017). A second randomised, double-blind, placebo-controlled trial in the clinic setting found the gel likewise improved the ability to perform procedures (Korpivaara 2021). Owner-scored outcomes and a single noise night in the pivotal trial are what keep this at LIKELY rather than higher. Drafted Nov 10, 2026 (VetMed build, topic #302); all figures from abstracts fetched and verified at drafting.

Korpivaara 2017: excellent or good effect in 72% on dexmedetomidine gel vs 37% on placebo over New Year's Eve fireworks (182 dogs)

Randomised, double-blind, placebo-controlled clinical-field study

Who: Dogs: 182 dogs with a history of acute anxiety and fear associated with fireworks, treated at home on New Year's Eve as needed up to five times — 89 dogs received dexmedetomidine oromucosal gel at subsedative doses and 93 received placebo; owners assessed the overall treatment effect and signs and extent of anxiety and fear.

Result: The overall treatment effect was statistically significant (P<0.0001). An excellent or good treatment effect was reported for a higher proportion of dogs treated with dexmedetomidine (64/89, 72 per cent) than those receiving placebo (34/93, 37 per cent). Dexmedetomidine-treated dogs expressed significantly (P<0.0314) fewer signs of fear and anxiety despite the noise of fireworks. No local tolerance or clinical safety concerns occurred during the study.

Watch out: Outcomes are owner assessments on a single fireworks night, and the study was run by the manufacturer's (Orion Pharma) group. The absolute rates are carded above (72% vs 37%) alongside the relative impression, per the relative-measure rule.

Korpivaara M, Laapas K, Huhtinen M et al. Dexmedetomidine oromucosal gel for noise-associated acute anxiety and fear in dogs-a randomised, double-blind, placebo-controlled clinical study. Vet Rec. 2017 Apr 8;180(14):356. PMID: 28213531. Registry ID: none in the record. MeSH: Animals · Anxiety · Behavior, Animal · Dexmedetomidine · Dogs · Double-Blind Method · Fear · Female · Gels · Male · Noise · Placebos · Treatment Outcome

Korpivaara 2021: dexmedetomidine gel also eased veterinary-visit procedures — excellent procedure ability in 40.7% and 33.3% vs 4.3% on placebo

Randomised, double-blind, placebo-controlled clinical pilot study (clinic setting)

Who: Dogs: 76 eligible dogs previously reported to suffer fear and anxiety during veterinary visits, in a randomised, double-blind, placebo-controlled, parallel-group, multicentre clinical-field study, randomly assigned to dexmedetomidine 0.1 mg/g oromucosal gel at 125 µg/m² (n = 27) or 250 µg/m² (n = 24), or an equivalent volume of placebo gel (n = 23), for a physical examination and one short minor veterinary or husbandry procedure.

Result: The investigator's ability to perform the intended procedure was excellent for 40.7% of dogs receiving dexmedetomidine 125 µg/m² and 33.3% of those receiving 250 µg/m², compared with only 4.3% of placebo dogs; the overall treatment effect was statistically significant (p = 0.03). Dexmedetomidine-treated dogs significantly more commonly showed relaxed body posture (p < 0.01) and more relaxed behaviour when entering the examination room (p = 0.02). There were very few adverse events, and treated animals were not sedated.

Watch out: This second trial answers a neighbouring question (clinic-visit anxiety, not noise aversion) and is labelled a pilot study; it supports the gel's anxiolytic effect generally rather than replicating the fireworks result directly. Manufacturer-run (Orion).

Korpivaara M, Huhtinen M, Aspegrén J et al. Dexmedetomidine oromucosal gel reduces fear and anxiety in dogs during veterinary visits: A randomised, double-blind, placebo-controlled clinical pilot study. Vet Rec. 2021 Dec;189(12):e832. PMID: 34448217. Registry ID: none in the record. MeSH: Animals · Anxiety · Anxiety Disorders · Dexmedetomidine · Dogs · Fear · Pilot Projects

Synthesis: subsedative dexmedetomidine gel measurably reduces acute noise anxiety in dogs

Synthesis

Who: Synthesis of the cards above: Korpivaara 2017 (randomised double-blind placebo-controlled field study, 182 dogs, fireworks) and Korpivaara 2021 (randomised double-blind placebo-controlled pilot, 76 dogs, clinic visits).

Result: The pivotal noise trial is large for veterinary behaviour medicine, blinded and placebo-controlled, with a decisive owner-scored separation (72% vs 37% excellent or good effect) and no safety concerns at subsedative doses; the clinic pilot points the same way on investigator-scored outcomes. LIKELY reflects strong but owner/investigator-scored, largely single-sponsor evidence.

Watch out: Correct oromucosal dosing by the owner (gloves, no swallowing by the dog, dose by body surface area) is part of the intervention as trialled; effects in thunderstorm phobia specifically were not separately trialled in these records.

Synthesis of Korpivaara M et al. PMID: 28213531; Korpivaara M et al. PMID: 34448217. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.